Acute promyelocytic leukemia with PML::RARA fusion

APL affects immature myeloid cells called promyelocytes. In the form described here, a PML::RARA fusion disrupts their normal development. This genetic finding distinguishes APL from other AML and explains why its main medicines work differently.

APL can develop in children and adults. Blood and marrow testing identifies the abnormal cells, and molecular or chromosome testing confirms the fusion. Suspected APL requires immediate specialist care because bleeding complications can develop before all test results are available.

PML::RARA usually forms when parts of chromosomes 15 and 17 rearrange in a blood-forming cell. This is generally an acquired change, not something passed from a parent to a child.

Most people have no identifiable cause. APL can occasionally follow previous cancer treatment. It cannot be caught from another person. Other rare rearrangements can resemble APL, but their response to treatment may differ and requires precise diagnosis.

APL can reduce normal red cells and platelets, causing tiredness, breathlessness, bruising or bleeding. It can also disrupt the clotting system, so serious bleeding and abnormal clotting may occur together.

During treatment, differentiation syndrome is another possible emergency: maturing leukemia cells can trigger inflammation, fluid retention and breathing difficulties. The care team monitors for this and provides prompt treatment when needed.

All-trans retinoic acid (ATRA) helps abnormal promyelocytes mature. Arsenic trioxide is also a central treatment. Many patients receive ATRA with arsenic; higher-risk disease may require additional treatment to control the leukemia-cell count, including chemotherapy in some protocols.

Treatment includes intensive support for bleeding and clotting abnormalities. After the initial response, consolidation and molecular testing help establish whether the PML::RARA signal has cleared and whether it returns.

Transplant is generally unnecessary in first remission. In relapse, treatment depends on what was given before and the molecular response. An autologous transplant, using the person’s own collected cells, may be considered after molecular remission. Allogeneic transplantation may be considered when disease persists or for selected further relapses.

The early days may involve hospitalization, frequent blood tests and transfusions even while medicines are beginning to work. Later treatment can include repeated clinic visits and molecular monitoring. A good early response does not make follow-up unnecessary.

ATRA and arsenic have side effects that need monitoring, including differentiation syndrome; arsenic can also affect heart rhythm and electrolytes. The treatment team explains which symptoms need an urgent call and how follow-up fits around home, school or work.

A registry donor is not part of the usual first-line APL treatment. An autologous transplant also does not use a registry donor.

For a person who needs allogeneic transplantation after relapse, a relative or unrelated donor may be considered, with alternative graft options assessed by the transplant team. General donor recruitment supports people with many conditions; it should not be presented as the treatment most people with APL require.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?